| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Protein kinase inhibitors 1 targets homeodomain-interacting protein kinase 2 (HIPK2). HIPK2 is a serine/threonine kinase that plays critical roles in DNA damage response, apoptosis, transcription regulation, and development. The compound has high affinity for HIPK2, with an IC₅₀ of 74 nM and a Kd of 9.5 nM. It is a potent and selective inhibitor. The compound may also inhibit other kinases at higher concentrations, but its selectivity for HIPK2 is its defining feature.
|
|---|---|
| ln Vitro |
In vitro, protein kinase inhibitors 1 potently inhibits HIPK2 kinase activity with an IC₅₀ of 74 nM and a Kd of 9.5 nM. The compound's high affinity for HIPK2 makes it a valuable tool for studying HIPK2-mediated signaling pathways. Inhibition of HIPK2 by this compound can be used to investigate the role of HIPK2 in DNA damage response, p53 activation, apoptosis, and transcriptional regulation. No other in vitro activities have been reported for this compound.
|
| ln Vivo |
In vivo activity of protein kinase inhibitors 1 has not been extensively characterized in animal models. No specific in vivo efficacy studies have been reported for this compound. The compound is primarily used as a research tool for in vitro studies of HIPK2 function. Future studies may involve administration of the compound in animal models to evaluate its effects on HIPK2-mediated processes in vivo. Currently, no in vivo data are available.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for protein kinase inhibitors 1 typically employ purified recombinant HIPK2 enzyme. The compound is incubated with the kinase, ATP, and a suitable peptide substrate in kinase buffer. Kinase activity is measured by incorporation of ³²P-ATP into the substrate or by using a luminescent kinase assay (e.g., ADP-Glo). IC₅₀ values are determined by measuring kinase activity at various inhibitor concentrations and fitting the data to a dose-response curve. Kd values are determined by surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC).
|
| Cell Assay |
In vitro cell-based assays for protein kinase inhibitors 1 typically employ cell lines that express HIPK2, such as cancer cell lines or cells treated with DNA-damaging agents that activate HIPK2. Cells are treated with various concentrations of the compound (typically 0.1-10 μM) for various time periods. HIPK2 activity is assessed by measuring the phosphorylation of downstream substrates (e.g., p53 at Ser46) by Western blot. Apoptosis is evaluated by measuring caspase activation, Annexin V staining, or PARP cleavage. Cell viability is assessed by MTT or CCK-8 assays.
|
| Animal Protocol |
In vivo animal studies have not been reported for protein kinase inhibitors 1. No animal models have been used to evaluate its pharmacokinetics, efficacy, or toxicology. The compound is primarily used as a research tool for in vitro studies. Future studies may involve administration of the compound in rodent models to evaluate its effects on HIPK2-mediated processes in vivo. Currently, no in vivo data are available.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of protein kinase inhibitors 1 have not been characterized. No absorption, distribution, metabolism, or excretion studies have been conducted for this compound. As a small molecule with a molecular weight of 383.42, the compound may have reasonable oral bioavailability and cell permeability. However, these properties have not been experimentally determined. Further studies are needed to evaluate the compound's PK profile.
|
| Toxicity/Toxicokinetics |
The toxicity profile of protein kinase inhibitors 1 has not been characterized in preclinical studies. No acute toxicity, genotoxicity, or chronic toxicity studies have been reported. The compound is intended for research use only and is not approved for human therapeutic applications. Standard safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Protein kinase inhibitors 1 is a research-grade small-molecule inhibitor of HIPK2. It has a molecular formula of C₁₈H₁₇N₅O₃S and a molecular weight of 383.42. The compound is a potent HIPK2 inhibitor with an IC₅₀ of 74 nM and a Kd of 9.5 nM. It is not an approved therapeutic drug and has no clinical trial history. The compound is supplied as a solid powder and should be stored at -20°C. It is soluble in DMSO. The compound is intended for research use only and not for human or veterinary use.
|
| Molecular Formula |
C18H18CLN5O3S
|
|---|---|
| Molecular Weight |
419.885221004486
|
| Exact Mass |
383.105
|
| CAS # |
1365986-44-2
|
| Related CAS # |
Protein kinase inhibitor 1 hydrochloride;2321337-71-5
|
| PubChem CID |
132274054
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
0.4
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
27
|
| Complexity |
754
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
Cl.S1C(NC(/C/1=C/C1=CNC(C(=C1)C1=CN=C(C=C1)N1CCNCC1)=O)=O)=O
|
| InChi Key |
YHUKWWWCNSTFHL-RIYZIHGNSA-N
|
| InChi Code |
InChI=1S/C18H17N5O3S/c24-16-13(7-11(9-21-16)8-14-17(25)22-18(26)27-14)12-1-2-15(20-10-12)23-5-3-19-4-6-23/h1-2,7-10,19H,3-6H2,(H,21,24)(H,22,25,26)/b14-8+
|
| Chemical Name |
(5E)-5-[[6-oxo-5-(6-piperazin-1-ylpyridin-3-yl)-1H-pyridin-3-yl]methylidene]-1,3-thiazolidine-2,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3816 mL | 11.9079 mL | 23.8158 mL | |
| 5 mM | 0.4763 mL | 2.3816 mL | 4.7632 mL | |
| 10 mM | 0.2382 mL | 1.1908 mL | 2.3816 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
